MAGGI, CLAUDIA
 Distribuzione geografica
Continente #
EU - Europa 2.081
NA - Nord America 1.439
AS - Asia 1.072
SA - Sud America 100
AF - Africa 26
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.734
Nazione #
US - Stati Uniti d'America 1.407
DE - Germania 1.063
CN - Cina 460
GB - Regno Unito 433
SG - Singapore 295
SE - Svezia 158
HK - Hong Kong 123
IT - Italia 122
BR - Brasile 75
RU - Federazione Russa 70
NL - Olanda 56
FR - Francia 46
IE - Irlanda 42
IN - India 35
FI - Finlandia 33
ID - Indonesia 27
CA - Canada 26
TR - Turchia 22
JP - Giappone 21
VN - Vietnam 20
KR - Corea 19
AU - Australia 14
UA - Ucraina 12
CI - Costa d'Avorio 11
BE - Belgio 9
PL - Polonia 9
AR - Argentina 7
TH - Thailandia 7
BD - Bangladesh 6
DK - Danimarca 6
AT - Austria 5
EC - Ecuador 5
ES - Italia 5
IR - Iran 4
JO - Giordania 4
MX - Messico 4
UZ - Uzbekistan 4
CO - Colombia 3
IQ - Iraq 3
PK - Pakistan 3
SA - Arabia Saudita 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
MA - Marocco 2
PT - Portogallo 2
TW - Taiwan 2
AM - Armenia 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
HR - Croazia 1
JM - Giamaica 1
KW - Kuwait 1
LT - Lituania 1
LV - Lettonia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SN - Senegal 1
SR - Suriname 1
TL - Timor Orientale 1
TN - Tunisia 1
UY - Uruguay 1
Totale 4.734
Città #
Frankfurt am Main 955
Southend 398
Ashburn 190
Chandler 175
Singapore 173
Hong Kong 119
Beijing 101
Seattle 89
Fairfield 84
Milan 83
Dallas 57
Wilmington 53
Munich 48
Princeton 48
Cambridge 46
Houston 45
Council Bluffs 44
Dublin 40
Woodbridge 40
Los Angeles 35
Phoenix 31
Santa Clara 27
Nanjing 23
Ann Arbor 22
Dearborn 22
Columbus 20
Guangzhou 20
Des Moines 19
Toronto 18
Jakarta 17
Istanbul 16
Shanghai 16
Shenyang 16
The Dalles 15
Tokyo 15
Buffalo 14
Eitensheim 14
San Diego 14
Bengaluru 13
Moscow 13
Jinan 12
Zhengzhou 12
Abidjan 11
Hangzhou 11
New York 10
Brussels 9
Changsha 9
Nanchang 9
Cangzhou 8
Chicago 8
Falls Church 8
Grafing 8
Redwood City 8
Boardman 7
Fuzhou 7
Helsinki 7
Ho Chi Minh City 7
Silver Spring 7
Bexley 6
Hebei 6
Taiyuan 6
Tianjin 6
Turku 6
Amsterdam 5
Düsseldorf 5
Newark 5
Stockholm 5
Amman 4
Andover 4
Haikou 4
Hanoi 4
Hefei 4
Jiaxing 4
Kunming 4
Ningbo 4
Nuremberg 4
Sydney 4
São Paulo 4
Warsaw 4
Wroclaw 4
Bangkok 3
Brasília 3
Charlotte 3
Langfang 3
Lanzhou 3
Madrid 3
Melbourne 3
Orem 3
Porto Alegre 3
Pune 3
Rio de Janeiro 3
Rochester 3
San Francisco 3
Shenzhen 3
Tashkent 3
Abingdon 2
Arezzo 2
Atlanta 2
Baku 2
Berlin 2
Totale 3.503
Nome #
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase 301
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : A clinical and translational study 286
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status 270
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 268
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation 229
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan 228
Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens 214
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives 209
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer 208
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma 206
TP53 mutations in advanced colorectal cancer : the dark side of the moon 206
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles 205
Role of cMET in the development and progression of colorectal cancer 194
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases 190
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis 189
Role of MGMT as biomarker in colorectal cancer 188
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis 186
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil : a meta-analysis of published trials 182
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer 178
Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer : A systematic review and meta-analysis of published trials 177
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study 163
Treatment of elderly patients with metastatic renal cell carcinoma 151
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab 146
In reply 146
Totale 4.920
Categoria #
all - tutte 11.686
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.686


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021144 0 0 0 0 0 17 7 18 49 17 21 15
2021/2022310 56 10 5 13 20 16 13 13 21 55 13 75
2022/2023508 58 68 55 46 50 85 5 35 77 5 16 8
2023/2024908 4 20 15 8 78 16 137 126 68 156 136 144
2024/20251.066 130 115 101 129 51 28 25 73 39 107 78 190
2025/2026688 183 86 158 110 149 2 0 0 0 0 0 0
Totale 4.920